X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-03-17 | VRTX | Wagner Charles F Jr | EVP, CFO | S - Sale | $296.39 | -2,000 | 51,379 | -4% | -$592,786 | ||||||
2023-03-16 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $300.59 | -2,746 | 49,268 | -5% | -$825,423 | ||||||
| M | 2023-03-10 | VRTX | Wagner Charles F Jr | EVP, CFO | S - Sale | $291.98 | -4,754 | 53,379 | -8% | -$1,388,054 | |||||
2023-02-27 | VRTX | Tatsis Ourania | EVP, Chief Reg., Quality Offic | S - Sale | $287.48 | -354 | 56,805 | -1% | -$101,768 | ||||||
2023-02-27 | VRTX | Arbuckle Stuart A | EVP, COO | S - Sale | $287.47 | -5,034 | 56,696 | -8% | -$1,447,143 | ||||||
2023-02-27 | VRTX | Ambrose Kristen | SVP, Chief Accounting Officer | S - Sale | $287.55 | -1,207 | 7,303 | -14% | -$347,072 | ||||||
2023-02-27 | VRTX | Altshuler David | EVP, Global Research, CSO | S - Sale | $287.51 | -4,238 | 32,038 | -12% | -$1,218,449 | ||||||
2023-02-22 | VRTX | Arbuckle Stuart A | EVP, COO | S - Sale | $294.33 | -2,401 | 66,444 | -3% | -$706,679 | ||||||
2023-02-21 | VRTX | Tatsis Ourania | EVP, Chief Reg., Quality Offic | S - Sale | $293.75 | -480 | 60,467 | -1% | -$141,002 | ||||||
2023-02-21 | VRTX | Arbuckle Stuart A | EVP, COO | S - Sale | $293.75 | -2,402 | 68,845 | -3% | -$705,596 | ||||||
2023-02-21 | VRTX | Altshuler David | EVP, Global Research, CSO | S - Sale | $293.77 | -4,002 | 40,246 | -9% | -$1,175,676 | ||||||
2023-02-14 | VRTX | Tatsis Ourania | EVP, Chief Reg., Quality Offic | S - Sale | $298.52 | -320 | 65,445 | 0% | -$95,527 | ||||||
2023-02-14 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $300.40 | -2,181 | 59,734 | -4% | -$655,161 | ||||||
2023-02-14 | VRTX | Arbuckle Stuart A | EVP, COO | S - Sale | $298.68 | -6,398 | 75,745 | -8% | -$1,910,962 | ||||||
2023-02-14 | VRTX | Altshuler David | EVP, Global Research, CSO | S - Sale | $298.70 | -6,398 | 47,998 | -12% | -$1,911,108 | ||||||
2023-02-13 | VRTX | Tatsis Ourania | EVP, Chief Reg., Quality Offic | S - Sale | $298.99 | -275 | 65,765 | 0% | -$82,223 | ||||||
2023-02-13 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $300.39 | -113 | 61,915 | 0% | -$33,944 | ||||||
2023-02-13 | VRTX | Arbuckle Stuart A | EVP, COO | S - Sale | $298.92 | -4,887 | 82,143 | -6% | -$1,460,816 | ||||||
2023-02-13 | VRTX | Altshuler David | EVP, Global Research, CSO | S - Sale | $298.90 | -4,798 | 54,396 | -8% | -$1,434,126 | ||||||
| D | 2023-02-06 | VRTX | Altshuler David | EVP, Global Research, CSO | S - Sale+OE | $306.00 | -1,304 | 68,645 | -2% | -$399,022 | |||||
2023-01-31 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $325.00 | -106 | 37,998 | 0% | -$34,450 | ||||||
| D | 2023-01-31 | VRTX | Sachs Bruce I | Dir | S - Sale+OE | $325.01 | -1,200 | 41,210 | -3% | -$390,012 | |||||
2023-01-30 | VRTX | Carney Lloyd | Dir | S - Sale | $320.52 | -2,700 | 4,150 | -39% | -$865,406 | ||||||
| D | 2023-01-27 | VRTX | Lee Yuchun | Dir | S - Sale+OE | $322.03 | -1,429 | 1,875 | -43% | -$460,177 | |||||
| DM | 2023-01-25 | VRTX | Lee Yuchun | Dir | S - Sale+OE | $316.15 | -8,000 | 1,875 | -81% | -$2,529,174 | |||||
2023-01-25 | VRTX | Kewalramani Reshma | CEO, Pres | S - Sale | $315.05 | -10,000 | 89,598 | -10% | -$3,150,500 | ||||||
| DM | 2023-01-23 | VRTX | Lee Yuchun | Dir | S - Sale+OE | $312.46 | -6,129 | 1,875 | -77% | -$1,915,044 | |||||
| DM | 2023-01-17 | VRTX | Lee Yuchun | Dir | S - Sale+OE | $312.04 | -4,442 | 1,875 | -70% | -$1,386,099 | |||||
2022-11-15 | VRTX | Altshuler David | EVP, Global Research, CSO | S - Sale | $308.61 | -34 | 36,077 | 0% | -$10,493 | ||||||
| D | 2022-11-07 | VRTX | Altshuler David | EVP, Global Research, CSO | S - Sale+OE | $303.04 | -1,303 | 36,077 | -3% | -$394,859 | |||||
2022-11-02 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $312.64 | -320 | 38,104 | -1% | -$100,045 | ||||||
2022-10-24 | VRTX | Bhatia Sangeeta N. | Dir | S - Sale | $310.00 | -621 | 4,040 | -13% | -$192,510 | ||||||
2022-10-18 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $300.31 | -1,791 | 39,192 | -4% | -$537,860 | ||||||
2022-08-15 | VRTX | Kewalramani Reshma | CEO, Pres | S - Sale | $305.06 | -11,689 | 99,598 | -11% | -$3,565,846 | ||||||
| D | 2022-08-15 | VRTX | Arbuckle Stuart A | EVP, COO | S - Sale+OE | $303.93 | -22,173 | 45,418 | -33% | -$6,738,991 | |||||
2022-08-15 | VRTX | Liu Joy | SVP, GC | S - Sale | $303.90 | -3,747 | 9,605 | -28% | -$1,138,723 | ||||||
| D | 2022-08-10 | VRTX | Arbuckle Stuart A | EVP, COO | S - Sale+OE | $300.41 | -180 | 61,020 | 0% | -$54,073 | |||||
2022-08-10 | VRTX | Liu Joy | SVP, GC | S - Sale | $300.32 | -36 | 13,352 | 0% | -$10,812 | ||||||
2022-08-08 | VRTX | Bhatia Sangeeta N. | Dir | S - Sale | $293.03 | -621 | 4,661 | -12% | -$181,972 | ||||||
2022-08-09 | VRTX | Liu Joy | SVP, GC | S - Sale | $300.00 | -946 | 13,388 | -7% | -$283,800 | ||||||
2022-08-09 | VRTX | Tatsis Ourania | EVP, Chief Reg., Quality Offic | S - Sale | $298.97 | -1,400 | 46,090 | -3% | -$418,557 | ||||||
| D | 2022-08-09 | VRTX | Arbuckle Stuart A | EVP, COO | S - Sale+OE | $300.67 | -5,690 | 61,136 | -9% | -$1,710,817 | |||||
| D | 2022-08-08 | VRTX | Altshuler David | EVP, Global Research, CSO | S - Sale+OE | $292.54 | -1,304 | 36,077 | -3% | -$381,469 | |||||
2022-07-29 | VRTX | Bhatia Sangeeta N. | Dir | S - Sale | $278.77 | -621 | 5,282 | -11% | -$173,116 | ||||||
| D | 2022-07-25 | VRTX | Leiden Jeffrey M | Exec COB | S - Sale+OE | $281.38 | -132,079 | 2,863 | -98% | -$37,164,481 | |||||
| D | 2022-07-19 | VRTX | Altshuler David | EVP, Global Research, CSO | S - Sale+OE | $288.65 | -17,865 | 36,077 | -33% | -$5,156,730 | |||||
2022-06-24 | VRTX | Kewalramani Reshma | CEO, Pres | S - Sale | $291.30 | -11,689 | 111,153 | -10% | -$3,405,006 | ||||||
2022-05-16 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $252.83 | -45 | 41,749 | 0% | -$11,377 | ||||||
2022-05-16 | VRTX | Arbuckle Stuart A | EVP, COO | S - Sale | $251.19 | -133 | 64,900 | 0% | -$33,408 | ||||||
2022-05-16 | VRTX | Liu Joy | SVP, GC | S - Sale | $252.88 | -133 | 14,334 | -1% | -$33,633 | ||||||
2022-05-04 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $275.09 | -36 | 41,660 | 0% | -$9,903 | ||||||
2022-05-02 | VRTX | Arbuckle Stuart A | EVP, COO | S - Sale | $263.98 | -306 | 64,900 | 0% | -$80,778 | ||||||
2022-05-02 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $259.16 | -320 | 41,696 | -1% | -$82,930 | ||||||
2022-05-02 | VRTX | Bhatia Sangeeta N. | Dir | S - Sale | $258.95 | -737 | 5,903 | -11% | -$190,842 | ||||||
2022-05-02 | VRTX | Wagner Charles F Jr | EVP, CFO | S - Sale | $258.83 | -343 | 42,730 | -1% | -$88,778 | ||||||
2022-04-29 | VRTX | Liu Joy | SVP, GC | S - Sale | $275.41 | -120 | 14,334 | -1% | -$33,049 | ||||||
2022-04-25 | VRTX | Ambrose Kristen | SVP, Chief Accounting Officer | S - Sale | $269.55 | -327 | 3,496 | -9% | -$88,143 | ||||||
| D | 2022-04-18 | VRTX | Lee Yuchun | Dir | S - Sale+OE | $284.23 | -2,000 | 1,875 | -52% | -$568,467 | |||||
| D | 2022-04-14 | VRTX | Lee Yuchun | Dir | S - Sale+OE | $289.06 | -2,000 | 1,875 | -52% | -$578,117 | |||||
2022-04-13 | VRTX | Leiden Jeffrey M | Exec COB | S - Sale | $289.04 | -15,789 | 74,600 | -17% | -$4,563,653 | ||||||
| DM | 2022-04-12 | VRTX | Lee Yuchun | Dir | S - Sale+OE | $284.27 | -4,000 | 1,875 | -68% | -$1,137,060 | |||||
| DM | 2022-04-08 | VRTX | Lee Yuchun | Dir | S - Sale+OE | $279.44 | -4,000 | 1,875 | -68% | -$1,117,740 | |||||
| D | 2022-04-08 | VRTX | Bhatia Sangeeta N. | Dir | S - Sale+OE | $280.20 | -1,907 | 5,191 | -27% | -$534,341 | |||||
| D | 2022-04-08 | VRTX | McGlynn Margaret G | Dir | S - Sale+OE | $280.22 | -5,000 | 1,099 | -82% | -$1,401,080 | |||||
| DM | 2022-04-06 | VRTX | Lee Yuchun | Dir | S - Sale+OE | $273.24 | -4,000 | 1,875 | -68% | -$1,092,964 | |||||
2022-04-07 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $276.18 | -561 | 42,782 | -1% | -$154,935 | ||||||
| M | 2022-04-04 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $274.10 | -3,725 | 43,343 | -8% | -$1,021,005 | |||||
| DM | 2022-04-04 | VRTX | Lee Yuchun | Dir | S - Sale+OE | $270.11 | -4,000 | 1,875 | -68% | -$1,080,424 | |||||
2022-04-01 | VRTX | Wagner Charles F Jr | EVP, CFO | S - Sale | $264.76 | -2,582 | 43,620 | -6% | -$683,602 | ||||||
| D | 2022-03-31 | VRTX | McGlynn Margaret G | Dir | S - Sale+OE | $262.27 | -5,000 | 1,099 | -82% | -$1,311,346 | |||||
2022-03-17 | VRTX | Tatsis Ourania | EVP, Chief Reg., Quality Offic | S - Sale | $250.11 | -2,833 | 47,356 | -6% | -$708,572 | ||||||
2022-03-17 | VRTX | Wagner Charles F Jr | EVP, CFO | S - Sale | $250.15 | -3,171 | 46,202 | -6% | -$793,218 | ||||||
2022-03-17 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $250.06 | -2,122 | 48,412 | -4% | -$530,627 | ||||||
2022-02-25 | VRTX | Tatsis Ourania | EVP, Chief Reg., Quality Offic | S - Sale | $230.95 | -325 | 50,189 | -1% | -$75,058 | ||||||
2022-02-18 | VRTX | Tatsis Ourania | EVP, Chief Reg., Quality Offic | S - Sale | $231.00 | -519 | 53,104 | -1% | -$119,889 | ||||||
2022-02-18 | VRTX | Altshuler David | EVP, Global Research, CSO | S - Sale | $230.97 | -4,312 | 49,687 | -8% | -$995,949 | ||||||
2022-02-14 | VRTX | Altshuler David | EVP, Global Research, CSO | S - Sale | $232.02 | -2,444 | 57,438 | -4% | -$567,057 | ||||||
2022-02-02 | VRTX | Wagner Charles F Jr | EVP, CFO | S - Sale | $250.07 | -2,944 | 57,435 | -5% | -$736,206 | ||||||
2022-02-02 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $250.98 | -1,040 | 54,952 | -2% | -$261,017 | ||||||
| D | 2022-02-02 | VRTX | Altshuler David | EVP, Global Research, CSO | S - Sale+OE | $251.47 | -4,660 | 65,697 | -7% | -$1,171,842 | |||||
| D | 2022-01-28 | VRTX | McGlynn Margaret G | Dir | S - Sale+OE | $241.79 | -5,000 | 1,099 | -82% | -$1,208,960 | |||||
2021-11-15 | VRTX | Sachdev Amit | EVP, Chief Patient Officer | S - Sale | $187.19 | -51 | 48,383 | 0% | -$9,547 | ||||||
2021-11-15 | VRTX | Arbuckle Stuart A | EVP, COO | S - Sale | $187.26 | -3 | 41,243 | 0% | -$562 | ||||||
2021-11-15 | VRTX | Altshuler David | EVP, Global Research, CSO | S - Sale | $187.22 | -34 | 33,589 | 0% | -$6,365 | ||||||
2021-08-19 | VRTX | Kewalramani Reshma | CEO, Pres | P - Purchase | $195.65 | +10,000 | 73,754 | +16% | +$1,956,492 | ||||||
2021-08-02 | VRTX | Sachs Bruce I | Dir | P - Purchase | $197.91 | +15,000 | 41,210 | +57% | +$2,968,650 | ||||||
2021-06-02 | VRTX | Bhatia Sangeeta N. | Dir | S - Sale | $209.69 | -559 | 5,191 | -10% | -$117,216 | ||||||
2021-05-17 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $216.34 | -112 | 34,108 | 0% | -$24,230 | ||||||
2021-05-17 | VRTX | Sachdev Amit | EVP, Chief Patient Officer | S - Sale | $216.35 | -45 | 48,383 | 0% | -$9,736 | ||||||
2021-05-17 | VRTX | Liu Joy | SVP, GC | S - Sale | $216.34 | -112 | 8,253 | -1% | -$24,230 | ||||||
2021-05-17 | VRTX | Arbuckle Stuart A | EVP, Chief Comm, Ops Officer | S - Sale | $216.41 | -109 | 41,243 | 0% | -$23,589 | ||||||
2021-05-17 | VRTX | Altshuler David | EVP, Global Research, CSO | S - Sale | $216.36 | -79 | 33,589 | 0% | -$17,093 | ||||||
2021-05-03 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $218.43 | -960 | 34,108 | -3% | -$209,691 | ||||||
| D | 2021-04-27 | VRTX | Sachdev Amit | EVP, Chief Patient Officer | S - Sale+OE | $216.06 | -3,884 | 48,383 | -7% | -$839,193 | |||||
2021-04-05 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $214.14 | -1,686 | 35,834 | -4% | -$361,046 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |